NCT06632938

A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers

A Randomized, Single-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ABBV-382 in Healthy Adult Chinese Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single subcutaneous (SC) and intravenous (IV) doses of ABBV-382 in healthy adult Chinese volunteers.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ABBV-382	Subcutaneous (SC) Injection
DRUG	ABBV-382	Intravenous (IV) Infusion
DRUG	Placebo for ABBV-382	IV Infusion
DRUG	Placebo for ABBV-382	SC Injection

Timeline

• Start date: 2024-10-08
• Primary completion: 2025-05-15
• Completion: 2025-05-15
• First posted: 2024-10-09
• Last updated: 2025-05-30

Locations

1 site across 1 country: China